Menu
Not yet recruiting NCT07168551

Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients

Observational Hyperuricemia NAFLD (Nonalcoholic Fatty Liver Disease) Liver Fibrosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level ., *Imaging Studies:* 1- Ultrasound 2 - FibroScan, Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests..
Who it may be relevant to
Registry conditions: Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease), Liver Fibrosis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Association of Hyperuricemia and Non Alcoholic Fatty Liver Disease and Liver Fibrosis Risk in Adult Obese Patients

Overview

1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients. 2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression. 3 - To examine the relationship between serum uric acid levels and liver fibrosis severity\*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD. 4- To identify potential mechanisms underlying the association\*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.

Detailed description

Hyperuricemia is associated with nonalcoholic fatty liver disease (NAFLD), whereas whether the association differed by hyperuricemia onset age remained unclear. This study sought to investigate the associations of hyperuricemia onset age with the risk of incident NAFLD across adulthood.

Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD). Since both serum uric acid (SUA) and obesity are essential components of metabolic syndrome (MetS), it is uncertain whether the incidence of NAFLD results from serum uric acid, obesity, or other potential factors based on previous studies.

Interventions

  • Diagnostic test *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .
    Lab methods
  • Radiation *Imaging Studies:* 1- Ultrasound 2 - FibroScan
    Imaging
  • Device Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
    Instrument

Primary outcome measures

  • Prevalence of NAFLD [Time frame: 1 year]
Secondary outcome measures (1)
  • Serum uric acid level [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Age: Adults (typically 18-65 years old)

2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg/m²

3- Hyperuricemia : Elevated serum uric acid levels (typically > 7 mg/dL for men and > 6 mg/dL for women)

Exclusion criteria

  • excessive alcohol consumption ( > 20 gm /day in men and 10 in g /day in women )

2- use of steatogenic within the past 6 months

3- positive test for hepatitis B surface antigen and hepatitis B core antibody

4- Drug induced liver injury and autoimmune hepatitis

5 - cirrhosis and other causes of liver disease

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07168551 · UNLF

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗